hLF1-11 + fluconazole

hLF1-11 + fluconazole is an **experimental combination therapy** consisting of hLF1-11, a synthetic peptide derived from the first 11 amino acids of human lactoferrin, and fluconazole, an antifungal small molecule of the triazole class. The combination exhibits **synergistic antifungal activity** against various Candida species, including fluconazole-resistant Candida albicans, C. glabrata, C. krusei, C. parapsilosis, and C. tropicalis. The mechanism involves hLF1-11 initiating mitochondrial activation and membrane permeability changes in the fungal cell, increasing ATP and ROS production, followed by fluconazole acting in the effector phase, leading to fungal death. Studies report that pre-treatment with hLF1-11 renders fluconazole-resistant strains sensitive to fluconazole. The combination aims to overcome certain forms of antifungal resistance and is under investigation in preclinical and early clinical scenarios[1][2][3][4].

Other names

hLF(1-11) + fluconazole